Cancer drugmaker Seattle Genetics reported stronger-than-expected revenues for the second quarter as its stock rose more than 8 percent in after-hours trading.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,